Contineum Therapeutics Inc. Class A Common Stock (CTNM) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Contineum Therapeutics In...

    NASDAQ: CTNM · Real-Time Price · USD
    11.35
    0.60 (5.58%)
    At close: Oct 03, 2025, 3:59 PM
    11.13
    -1.94%
    After-hours: Oct 03, 2025, 04:22 PM EDT

    Contineum Therapeutics Class A Common Stock Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 50M n/a n/a
    Cost of Revenue
    		 n/a n/a 329K n/a
    Gross Profit
    		 n/a 50M -329K n/a
    Operating Income
    		 -50.89M -16.08M -22.72M -28.65M
    Interest Income
    		 8.9M 4.61M 761K 77K
    Pretax Income
    		 -42.26M 23.17M -24.25M -29M
    Net Income
    		 -42.26M 22.72M -24.25M -29M
    Selling & General & Admin
    		 12.47M 6.32M 6.63M 6.29M
    Research & Development
    		 38.42M 27.6M 16.89M 22.36M
    Other Expenses
    		 n/a 32.15M -92K -91K
    Operating Expenses
    		 50.89M 66.08M 22.39M 28.65M
    Interest Expense
    		 n/a 208K 388K 332K
    Selling & Marketing Expenses
    		 n/a n/a 805K n/a
    Cost & Expenses
    		 50.89M 66.08M 22.72M 28.65M
    Income Tax Expense
    		 n/a 450K n/a 241K
    Shares Outstanding (Basic)
    		 19.35M 25.28M 25.13M 25.13M
    Shares Outstanding (Diluted)
    		 19.35M 25.28M 25.13M 25.13M
    EPS (Basic)
    		 -2.18 0.90 -0.97 -1.15
    EPS (Diluted)
    		 -2.18 0.90 -0.97 -1.15
    EBITDA
    		 -42M 23.57M -23.54M -28.34M
    EBIT
    		 -42.26M 23.38M -23.86M -28.67M
    Depreciation & Amortization
    		 258K 195K 329K 325K

    Add to Watchlist